Spots Global Cancer Trial Database for acute lymphoblastic leukemia, adult
Every month we try and update this database with for acute lymphoblastic leukemia, adult cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALL | NCT05127148 | Acute Lymphobla... | Evaluation of s... | 18 Years - 40 Years | Grupo Argentino de Tratamiento de la Leucemia Aguda | |
| Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine | NCT06060782 | Burkitt Lymphom... Lymphoblastic L... Acute Lymphobla... | Thiotepa, cyclo... | 18 Years - 65 Years | Fifth Affiliated Hospital, Sun Yat-Sen University | |
| CAR T-cell Therapy in Patients With Renal Dysfunction | NCT05909059 | Non-hodgkin Lym... Multiple Myelom... Acute Lymphobla... | Fludarabine Cyclophosphamid... | 18 Years - | Northside Hospital, Inc. | |
| Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | NCT03676504 | Acute Lymphobla... Acute Lymphobla... Chronic Lymphoc... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... | CD19.CAR T Cell... Fludarabine Cyclophosphamid... | 3 Years - | University Hospital Heidelberg | |
| Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL | NCT04554459 | Acute Lymphobla... Ph+ ALL Newly Diagnosed | Ponatinib 15 MG... | 18 Years - 99 Years | Institute of Hematology and Blood Transfusion, Czech Republic | |
| Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL | NCT04554459 | Acute Lymphobla... Ph+ ALL Newly Diagnosed | Ponatinib 15 MG... | 18 Years - 99 Years | Institute of Hematology and Blood Transfusion, Czech Republic | |
| Prospective Observational Study on Incidence of Invasive Fungal Infections Among Patients With Acute Lymphoblastic Leukemia Ph-negative | NCT05750706 | Acute Lymphobla... Invasive Fungal... | observation of ... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Study in Adult Ph-positive ALL | NCT04688983 | Acute Lymphobla... | Ponatinib Blinatumomab Imatinib | 55 Years - | Cardiff University | |
| Prospective Observational Study on Incidence of Invasive Fungal Infections Among Patients With Acute Lymphoblastic Leukemia Ph-negative | NCT05750706 | Acute Lymphobla... Invasive Fungal... | observation of ... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | NCT06206174 | Hematologic Mal... Non Hodgkin Lym... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... | TGRX-814 | 18 Years - | Shenzhen TargetRx, Inc. | |
| CD19-CAR-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia | NCT04605666 | Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... | CD19-CAR-T2 Cel... | 18 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab | NCT03982992 | B Cell Precurso... B-Cell Acute Ly... Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... | Blinatumomab in... | 18 Years - | Ludwig-Maximilians - University of Munich | |
| High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD | NCT05895201 | Bone Marrow Tra... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Chronic Myelomo... | Sitagliptin Bortezomib Cyclophosphamid... | 18 Years - | Indiana University | |
| Determining the Mechanisms of Loss of CAR T Cell Persistence | NCT05809284 | Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... | - 25 Years | University College, London | ||
| High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD | NCT05895201 | Bone Marrow Tra... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Chronic Myelomo... | Sitagliptin Bortezomib Cyclophosphamid... | 18 Years - | Indiana University | |
| Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia | NCT03339700 | Acute Lymphobla... | Gemcitabine Busulfan Cyclophosphamid... Allogeneic Hema... | 18 Years - 60 Years | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | |
| Determining the Mechanisms of Loss of CAR T Cell Persistence | NCT05809284 | Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... | - 25 Years | University College, London | ||
| Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | NCT03676504 | Acute Lymphobla... Acute Lymphobla... Chronic Lymphoc... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... | CD19.CAR T Cell... Fludarabine Cyclophosphamid... | 3 Years - | University Hospital Heidelberg | |
| Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO | NCT06025682 | Acute Lymphobla... Infections Bacterial Infec... Viral Infection Fungal Infectio... Acute Lymphobla... Acute Lymphobla... | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | ||
| High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD | NCT05895201 | Bone Marrow Tra... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Chronic Myelomo... | Sitagliptin Bortezomib Cyclophosphamid... | 18 Years - | Indiana University | |
| Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab | NCT03982992 | B Cell Precurso... B-Cell Acute Ly... Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... | Blinatumomab in... | 18 Years - | Ludwig-Maximilians - University of Munich | |
| International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia | NCT03705507 | Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... | Selumetinib Dexamethasone | - | University of Birmingham |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
